AI assistant
ORTHOCELL LIMITED — Capital/Financing Update 2017
Dec 27, 2017
65477_rns_2017-12-27_85571072-86c7-4b5d-afdc-966e78fb6c05.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [594 x 111] intentionally omitted <==
Share Purchase Plan Closing Date Extended
Perth, Australia; 28 December 2017: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) advises that to allow shareholders additional time to participate in its Share Purchase Plan (Plan) the Closing Date has been extended until Friday 5 January 2018 .
Under the Plan, OCC is giving eligible shareholders the opportunity to purchase up to $15,000 worth of fully paid ordinary shares in OCC (Shares) at an issue price of $0.34 per Share which is the same price as the recently completed placement, irrespective of the size of their shareholding, without incurring brokerage or transaction costs.
The right to participate under the Plan is optional and is available exclusively to shareholders who are registered as holders of Shares at 5.00pm (AEDT) on the Record Date of 12 December 2017 and whose registered address is in Australia or New Zealand.
A revised timetable is set out below:
| whose registered address is in Australia or New Zealand. A revised timetable is set out below: |
|
|---|---|
| Record Date for Share Purchase Plan | 5pm, AEDT, 12 December 2017 |
| Share Purchase Plan and Placement Announced | 13 December 2017 |
| Offer Letter and Section 708A “Cleansing Notice” lodged with ASX |
15 December 2017 |
| Share Purchase Plan booklet sent to shareholders | 15 December 2017 |
| Share Purchase Plan Opened | 18 December 2017 |
| Closing date for Share Purchase Plan | 5 January 2018 |
| Lodge Appendix 3B, Issue of new shares under the Share Purchase Plan |
12 January 2018 |
| Quotation on ASX of new shares under the Share Purchase Plan |
15 January 2018 |
These dates are indicative only. OCC may vary the dates and times of the Offer without notice. Accordingly, shareholders are encouraged to submit their Entitlement and Acceptance Forms as early as possible.
Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au
==> picture [594 x 111] intentionally omitted <==
For more information, please contact:
General enquiries
Investor and Media enquiries
Paul Anderson
Orthocell Limited, Managing Director P: +61 8 9360 2888 E: [email protected]
Ben Walsh WE Buchan P: + 61 411 520 012 E: [email protected]
About Orthocell Limited
Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.
For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter @Orthocellltd and Linkedin www.linkedin.com/company/orthocell-ltd
Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au